Summary
Vertex Pharmaceuticals Incorporated (VRTX) filed an 8-K on July 24, 2003, to disclose its financial results for the quarter ended June 30, 2003. This report primarily serves to provide investors with timely information regarding the company's performance. The details of these financial results are presented in a press release attached as Exhibit 99.1 to this filing. As per SEC procedural guidance, the information is furnished under Regulation FD disclosure. This means that while the information is being made public, it is not being formally "filed" for purposes of Section 18 of the Exchange Act, nor is it automatically incorporated into other SEC filings unless specifically referenced. Investors should refer to Exhibit 99.1 for the comprehensive financial data and operational updates.
Key Highlights
- 1Vertex Pharmaceuticals filed an 8-K on July 24, 2003, to report Q2 2003 financial results.
- 2The company issued a press release detailing its financial performance for the quarter ended June 30, 2003.
- 3The press release, considered Exhibit 99.1, contains the substantive financial information.
- 4The filing is made under Regulation FD Disclosure (Item 9) to ensure broad public dissemination of the information.
- 5The disclosed information is furnished and not formally "filed" under Section 18 of the Exchange Act, meaning it does not carry the same liabilities unless incorporated by reference.
- 6Investors seeking specific financial metrics and performance details should review Exhibit 99.1.